Itraconazole: pharmacology, clinical experience and future development
The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
Itraconazole is an orally active, broad-spectrum, triazole antifungal agent which has a higher affinity for fungal cytochrome P-450 than ketoconazole but a low affinity for mammalian cytochrome P-450. Itraconazole has a broader spectrum of activity than other azole antifungals and shows interesting pharmacokinetic features in terms of its tissue distribution. These properties have resulted in reduced treatment times for a number of diseases such as vaginal candidiasis, as well as effective oral treatment of several deep mycoses, including aspergillosis and candidiasis. Currently itraconazole is registered in 42 countries for the treatment of systemic fungal infections. Further development is concentrating on antifungal prophylaxis as well as on an oral solution and an intravenous formulation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“When taking ITZ with other medications, caution should be exercised because there may be drug interactions mediated by the cytochrome P450 enzyme 3A4 system, even though dosages up to 400 mg day−1 are usually well-tolerated and rarely result in significant adverse effects.11”
From Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights (2026) · cites this paper as [11]
In the citing paper
“When taking ITZ with other medications, caution should be exercised because there may be drug interactions mediated by the cytochrome P450 enzyme 3A4 system, even though dosages up to 400 mg day−1 are usually well-tolerated and rarely result in significant adverse effects.11”
From Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights (2026) · cites this paper as [11]
Citations
Cites
46th Interscience Conference on Antimicrobial Agents and Chemotherapy
McConnell, J. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70621-1 · Cited by 541
Olkkola, K. T., Backman, J. T., & Neuvonen, P. J. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.60 · Cited by 409
The Clinical Pharmacokinetics of Itraconazole: An Overview
Heykants, J., Van Peer, A., Van de Velde, V., Van Rooy, P., Meuldermans, W., Lavrijsen, K., Woestenborghs, R., Van Cutsem, J., & Cauwenbergh, G. (1989) · Mycoses · doi:10.1111/j.1439-0507.1989.tb02296.x · Cited by 404
Biochemical Targets for Antifungal Azole Derivatives: Hypothesis on the Mode of Action
Vanden Bossche, H. (1985) · Current Topics in Medical Mycology · doi:10.1007/978-1-4613-9547-8_12 · Cited by 321
Varhe, A., Olkkola, K. T., & Neuvonen, P. J. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.184 · Cited by 278
Adverse events associated with itraconazole in 189 patients on chronic therapy
Tucker, R. M., Haq, Y., Denning, D. W., & Stevens, D. A. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/26.4.561 · Cited by 199
Antifungal Prophylaxis with Itraconazole in Prolonged Neutropenia: Correlation with Plasma Levels
Boogaerts, M. A., Verhoef, G. E., Zachee, P., Demuynck, H., Verbist, L., & De Beule, K. (1989) · Mycoses · doi:10.1111/j.1439-0507.1989.tb02299.x · Cited by 189
Tucker, R. M., Denning, D. W., Hanson, L. H., Rinaldi, M. G., Graybill, J. R., Sharkey, P. K., Pappagianis, D., & Stevens, D. A. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.1.165 · Cited by 183
Mechanisms and clinical impact of antifungal drug resistance
BOSSCHE, H. V., Warnock, D. W., Dupont, B., Kerridge, D., Gupta, S. S., Improvisi, L., Marichal, P., Odds, F. C., Provost, F., & Ronin, O. (1994) · Medical Mycology · doi:10.1080/02681219480000821 · Cited by 138
Effect of a Cola Beverage on the Bioavailability of Itraconazole in the Presence of H2 Blockers
Lange, D., Pavao, J. H., Wu, J., & Klausner, M. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04332.x · Cited by 136
Research works printed but not linked: 2
- De Beule K. Safety profile of itraconazole therapy in vaginal candidosis, dermatomycosis and onychopmycosis. A review Current Therapeutic Research.
- Cartledge, 1994, Itraconazole cyclodextrin solution — effective treatment for HIV-related candidosis unresponsive to other azole therapy, J Antimicrob Chemother, 33, 1071, 10.1093/jac/33.5.1071 · DOI · Paper page
Cited by
Aspergillus fumigatus and Aspergillosis
Latgé, J.-P. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.310 · Cited by 2,307
Cyclodextrin-based pharmaceutics: past, present and future
Davis, M. E., & Brewster, M. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1576 · Cited by 1,996
Winston, D. J., Maziarz, R. T., Chandrasekar, P. H., Lazarus, H. M., Goldman, M., Blumer, J. L., Leitz, G. J., & Territo, M. C. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-9-200305060-00006 · Cited by 389
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Glasmacher, A., Prentice, A., Gorschlüter, M., Engelhart, S., Hahn, C., Djulbegovic, B., & Schmidt-Wolf, I. G. H. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.052 · Cited by 264
Metadata
- Authors
- De Beule, K.
- Venue
- International Journal of Antimicrobial Agents
- Publisher
- Elsevier BV
- Published
- 1996-02
- Volume
- 6
- Issue
- 3
- Pages
- 175-181
- ISSN
- 0924-8579 (ISSN-L)
- OpenAlex
- W2105749407
- Cited by
- 96
- References
- 33
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 5 · 2019: 3 · 2018: 3 · 2017: 2 · 2016: 3 · 2015: 6 · 2014: 4 · 2013: 4 · 2012: 3
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- International Journal of Antimicrobial Agents (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- itraconazole, triazole antifungals, cytochrome P450, pharmacokinetics, tissue distribution, vaginal candidiasis, aspergillosis, candidiasis, systemic fungal infection, antifungal prophylaxis, oral solution, intravenous formulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Itraconazole: pharmacology, clinical experience and future development. https://app.cochat.ai/papers/10.1016/0924-8579(95)00043-7
- The paper
- De Beule, K. (1996). Itraconazole: pharmacology, clinical experience and future development. International Journal of Antimicrobial Agents. https://doi.org/10.1016/0924-8579(95)00043-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.